文獻(xiàn)速遞 | 普諾賽®三季度高分文獻(xiàn)盤(pán)點(diǎn)
截止至2024年9月,全網(wǎng)收錄引用Pricella®產(chǎn)品的文獻(xiàn)共計(jì)11785篇,總IF值達(dá)68317.2!9月單月收錄328篇,總IF值1741.9分,其中26篇影響因子達(dá)10+,最高影響因子達(dá)27.7。
三季度發(fā)表文獻(xiàn)1054篇,總IF值5756.9分,最高影響因子達(dá)45.5,產(chǎn)品引用發(fā)表期刊包括Cell、Signal Transduction and Targeted Therapy、Molecular Cancer 等,發(fā)表機(jī)構(gòu)包括中國(guó)科學(xué)院動(dòng)物研究所、南京醫(yī)科大學(xué)第二附屬醫(yī)院、中山大學(xué)等。本期我們精選了4篇熱門(mén)領(lǐng)域的的高分文獻(xiàn)進(jìn)行分享,對(duì)主要研究?jī)?nèi)容進(jìn)行了簡(jiǎn)單介紹,旨在幫助科研人員了解最新研究方向及進(jìn)展。
文末有文獻(xiàn)獎(jiǎng)勵(lì)福利,不容錯(cuò)過(guò)哦!
- 鐵死亡 -
Pricella®三季度共發(fā)表
鐵死亡領(lǐng)域文獻(xiàn)61篇,最高IF值13.7
文獻(xiàn)分享:PRMT6/STAT1/ACSL1軸促進(jìn)糖尿病腎病鐵死亡
The PRMT6/STAT1/ACSL1 axis promotes ferroptosis in diabetic nephropathy(點(diǎn)擊查看原文)
上海交通大學(xué)醫(yī)學(xué)院附屬第一人民醫(yī)院朱敏敏、Zhang Jianhua和湖州市中心醫(yī)院孟志鵬團(tuán)隊(duì)發(fā)表的最新研究,表明PRMT6/STAT1/ACSL1功能軸在糖尿病腎?。―N)的發(fā)生發(fā)展中扮演著關(guān)鍵角色。通過(guò)構(gòu)建糖尿病腎病小鼠模型,發(fā)現(xiàn)蛋白精氨酸甲基轉(zhuǎn)移酶6(PRMT6)表達(dá)的下降與腎功能損傷的加劇密切相關(guān)。進(jìn)一步研究其分子機(jī)制,發(fā)現(xiàn)PRMT6表達(dá)降低,通過(guò)上調(diào)長(zhǎng)鏈?;?CoA合成酶家族成員1(ACSL1)的表達(dá),促進(jìn)了脂質(zhì)的過(guò)氧化,從而加劇鐵死亡。同時(shí)PRMT6與信號(hào)轉(zhuǎn)導(dǎo)及轉(zhuǎn)錄激活因子1(STAT1)協(xié)同調(diào)控ACSL1的轉(zhuǎn)錄,誘導(dǎo)多不飽和脂肪酸(PL-PUFAs)的產(chǎn)生,從而參與DN中的鐵死亡。這些發(fā)現(xiàn)提示PRMT6/STAT1/ACSL1軸可能成為預(yù)防和治療DN的新靶點(diǎn)。
? IF=13.7
? 作者單位:上海交通大學(xué)醫(yī)學(xué)院附屬第一人民醫(yī)院;湖州市中心醫(yī)院
? 發(fā)表期刊:Cell Death & Differentiation
? DOI:10.1038/s41418-024-01357-8
? PMID號(hào):39134684
? 所用普諾賽產(chǎn)品:
產(chǎn)品名稱 | 產(chǎn)品貨號(hào) |
人腎小球內(nèi)皮細(xì)胞 | CP-H061 |
HK-2 (人腎皮質(zhì)近曲小管上皮細(xì)胞) | CL-0109 |
人腎小球內(nèi)皮細(xì)胞完全培養(yǎng)基 | CM-H061 |
HK-2細(xì)胞專用培養(yǎng)基 | CM-0109 |
? 文獻(xiàn)相關(guān)圖片:
鐵死亡相關(guān)文獻(xiàn)
[1] R. Li, H. Yuan, C. Zhang, et al. Induced Ferroptosis Pathway by Regulating Cellular Lipid Peroxidation With Peroxynitrite Generator for Reversing "Cold" Tumors [J]. Small, 2024 September 16:e2404807. (IF=13.0)
[2] Y. Deng, L. Zeng, H. Liu, et al. Silibinin attenuates ferroptosis in acute kidney injury by targeting FTH1 [J]. Redox Biology. 2024 September 20; 77:103360. (IF=10.7)
[3] W. Wang, Z. Zhong, S. Peng, et al. "All-in-one" metal polyphenol network nanocapsules integrated microneedle patches for lipophagy fueled ferroptosis-mediated multimodal therapy [J]. Journal of Controlled Release, 2024 September; 373:599-616. (IF=10.5)
- 炎癥 -
Pricella®三季度共發(fā)表
炎癥領(lǐng)域文獻(xiàn)42篇,最高IF值27.7
文獻(xiàn)分享:發(fā)現(xiàn)牡荊素作為一種新的VDR激動(dòng)劑,可減輕慢性腸道炎癥向結(jié)直腸癌的轉(zhuǎn)變
中山大學(xué)唐海林、魏小麗,廣州中醫(yī)藥大學(xué)侯少貞以及廣州醫(yī)科大學(xué)蔡銘升團(tuán)隊(duì)合作發(fā)表的最新研究,探索了牡荊素緩解結(jié)腸炎相關(guān)結(jié)直腸癌(CAC)的作用機(jī)制。研究結(jié)果表明,維生素D受體(VDR)的缺乏加速了從慢性結(jié)腸炎到結(jié)直腸癌的進(jìn)展,而牡荊素可以特異性靶向VDR蛋白,促進(jìn)其轉(zhuǎn)運(yùn)到細(xì)胞核中發(fā)揮轉(zhuǎn)錄活性。此外,牡荊素依賴于VDR促進(jìn)巨噬細(xì)胞向M1表型的極化,并通過(guò)VDR調(diào)控吩嗪生物合成樣結(jié)構(gòu)域蛋白(PBLD)的轉(zhuǎn)錄激活。在骨髓特異性VDR敲除的小鼠模型中,對(duì)于中期CAC,牡荊素的保護(hù)作用失效。該研究明確了牡荊素靶向VDR并通過(guò)VDR/PBLD途徑調(diào)節(jié)巨噬細(xì)胞極化,從而減緩慢性結(jié)腸炎到結(jié)直腸癌的轉(zhuǎn)變,為臨床上延緩CAC病情進(jìn)展及探索治療方法提供了理論基礎(chǔ)。
? IF=27.7
? 作者單位:中山大學(xué)、廣州中醫(yī)藥大學(xué)、廣州醫(yī)科大學(xué)
? 發(fā)表期刊:Molecular Cancer
? DOI:10.1186/s12943-024-02108-6
? PMID號(hào):39272040
? 所用普諾賽產(chǎn)品:
產(chǎn)品名稱 | 產(chǎn)品貨號(hào) |
THP-1 (人單核細(xì)胞白血病) | CL-0233 |
RAW 264.7 (小鼠單核巨噬細(xì)胞白血病細(xì)胞) | CL-0190 |
CT26.WT (小鼠結(jié)腸癌細(xì)胞) | CL-0071 |
HCT 116 (人結(jié)腸癌細(xì)胞) | CL-0096 |
293T [HEK-293T](人胚腎細(xì)胞) | CL-0005 |
炎癥相關(guān)文獻(xiàn)
[1] X. Huang, L. Ye, N. An, et al. Macrophage autophagy protects against acute kidney injury by inhibiting renal inflammation through the degradation of TARM1 [J]. Autophagy, 2024 September 8:1-21. (IF=14.6)
[2] T. Li, Y. Li, J. Chen, et al. Hyperibone J exerts antidepressant effects by targeting ADK to inhibit microglial P2X7R/TLR4-mediated neuroinflammation [J]. Journal of Advanced Research, 2024 July 15:S2090-1232(24)00298-4. (IF=11.4)
[3] Z. Li, Q. Cheng, L. Lin, et al. Plasma Membrane-Derived Biomimetic Apoptotic Nanovesicles Targeting Inflammation and Cartilage Degeneration for Osteoarthritis [J]. Small Methods, 2024 July 22:e2400660. (IF=10.7)
巨噬細(xì)胞
Pricella®三季度共發(fā)表
巨噬細(xì)胞領(lǐng)域文獻(xiàn)61篇,最高IF值14.7
文獻(xiàn)分享:壞死性凋亡增強(qiáng)“別吃我”信號(hào)并誘導(dǎo)巨噬細(xì)胞胞外陷阱以促進(jìn)胰腺癌肝轉(zhuǎn)移
福建醫(yī)科大學(xué)陳實(shí)、田毅峰和王族偉團(tuán)隊(duì)合作發(fā)表的最新研究,探索了胰腺導(dǎo)管腺癌(PDAC)轉(zhuǎn)移的調(diào)控機(jī)制。研究通過(guò)RNA測(cè)序和免疫熒光發(fā)現(xiàn),早期肝轉(zhuǎn)移患者(T1M1)中混合譜系激酶結(jié)構(gòu)域樣假激酶(MLKL)表達(dá)升高,壞死性凋亡途徑增強(qiáng)。MLKL驅(qū)動(dòng)的壞死性凋亡招募巨噬細(xì)胞,增強(qiáng)腫瘤的“別吃我”CD47信號(hào),并誘導(dǎo)巨噬細(xì)胞胞外陷阱(METs)形成,激活CXCL8,進(jìn)一步促進(jìn)上皮-間質(zhì)轉(zhuǎn)化(EMT)和內(nèi)皮粘附。此外,METs降解細(xì)胞外基質(zhì),從而支持PDAC的肝轉(zhuǎn)移。靶向壞死性凋亡和CD47的治療可在體內(nèi)減少肝轉(zhuǎn)移。該研究揭示了壞死性凋亡通過(guò)逃避免疫監(jiān)視促進(jìn)PDAC轉(zhuǎn)移,也表明CD47阻斷結(jié)合MLKL抑制劑可能是克服T1M1困境和恢復(fù)根治性手術(shù)機(jī)會(huì)的潛在輔助免疫療法。
? IF=14.7
? 作者單位:福建醫(yī)科大學(xué)
? 發(fā)表期刊:Nature Communications
? DOI:10.1038/s41467-024-50450-6
? PMID號(hào):39025845
? 所用普諾賽產(chǎn)品:
產(chǎn)品名稱 | 產(chǎn)品貨號(hào) |
PUMC-HUVEC-T1 (SV40T轉(zhuǎn)化人臍靜脈內(nèi)皮細(xì)胞) | CL-0675 |
PUMC-HUVEC-T1細(xì)胞專用培養(yǎng)基 | CM-0675 |
巨噬細(xì)胞相關(guān)文獻(xiàn)
[1] C. Zhang, J. Li, D. Xu, et al. Surface Molecularly Engineered Mitochondria Conduct Immunophenotype Repolarization of Tumor-Associated Macrophages to Potentiate Cancer Immunotherapy [J]. Advanced Science, 2024 August 9:e2403044. (IF=14.3)
[2] H. Wang, M. Zheng, Y. Chen, et al. Macrophage-Targeted multifunctional nanoparticles for detection and treatment of intraplaque hemorrhage [J]. Chemical Engineering Journal, 2024 September 15; 496:153722. (IF=13.3)
[3] L. Yan, D. Li, S. Li, et al. Exosomes derived from 3D-cultured MSCs alleviate knee osteoarthritis by promoting M2 macrophage polarization through miR-365a-5p and inhibiting TLR2/Myd88/NF-κB pathway [J]. Chemical Engineering Journal, 2024 October 1; 497:154432. (IF=13.3)
[4] J. Zhou, S. Sun, J. Xu, et al. The magnesium-doped CSH/BCP promotes alveolar bone regeneration by mediating M2 macrophage polarization via miR-21–5p/Smad2 axis [J]. Composites Part B: Engineering, 2024 December; 287:111811. (IF=12.7)
線粒體
Pricella®三季度共發(fā)表
線粒體領(lǐng)域文獻(xiàn)29篇,最高IF值15.8
文獻(xiàn)分享:通過(guò)抑制代謝重編程的線粒體靶向多功能納米前藥用于對(duì)抗順鉑耐藥性肺癌
吉林大學(xué)中日聯(lián)誼醫(yī)院牟旭鵬團(tuán)隊(duì)最新發(fā)表的研究成果,設(shè)計(jì)了一種自組裝納米藥物遞送系統(tǒng)(LND-SS-Pt-TPP/HA-CD),該系統(tǒng)專門(mén)靶向順鉑耐藥的腫瘤細(xì)胞線粒體。系統(tǒng)中的β-環(huán)糊精修飾透明質(zhì)酸(HA-CD)包裹的前藥納米顆粒通過(guò)CD44受體在腫瘤細(xì)胞表面定向遞送,并通過(guò)三苯基磷基團(tuán)(TPP+)進(jìn)入細(xì)胞內(nèi)的線粒體。線粒體中的還原環(huán)境(谷胱甘肽和抗壞血酸)可降解藥物中的二硫鍵,釋放出順鉑和洛尼達(dá)明(LND)。順鉑通過(guò)損傷線粒體DNA來(lái)破壞線粒體功能,同時(shí)LND通過(guò)抑制己糖激酶II的活性來(lái)阻斷糖酵解供能,雙重打擊腫瘤細(xì)胞的能量代謝。LND-SS-Pt-TPP/HA-CD納米系統(tǒng)展示了其協(xié)同殺死順鉑耐藥肺癌細(xì)胞的潛力,為克服耐藥性癌癥提供了新的治療策略。
? IF=15.8
? 作者單位:吉林大學(xué)中日聯(lián)誼醫(yī)院
? 發(fā)表期刊:ACS Nano
? DOI:10.1021/acsnano.4c04024
? PMID號(hào):39088743
? 所用普諾賽產(chǎn)品:
產(chǎn)品名稱 | 產(chǎn)品貨號(hào) |
A549 [A-549] (人非小細(xì)胞肺癌細(xì)胞) | CL-0016 |
A549/DDP (人肺腺癌耐順鉑株) | CL-0519 |
? 文獻(xiàn)相關(guān)圖片:
線粒體相關(guān)文獻(xiàn)
[1] Q. Yu, J. Zhang, J. Li, et al. Sirtuin 5-Mediated Desuccinylation of ALDH2 Alleviates Mitochondrial Oxidative Stress Following Acetaminophen-Induced Acute Liver Injury [J]. Advanced Science, 2024 August 19:e2402710. (IF=14.3)
[2] Y. Wang, W. Li, Y. Guo, et al. Mitochondria Transplantation to Bone Marrow Stromal Cells Promotes Angiogenesis During Bone Repair [J]. Advanced Science, 2024 August 13:e2403201. (IF=14.3)
[3] Q. Pang, Z. Chen, J. Zhan, et al. Lesion-localized hydrogels functionalized with engineered extracellular matrix restore cellular homeostasis by enhancing mitochondrial energy metabolism for osteoarthritis therapy [J]. Chemical Engineering Journal, 2024 October 1; 497:155662. (IF=13.3)
[4] X. Zheng, T. Wang, J. Gong, et al. Biogenic derived nanoparticles modulate mitochondrial function in cardiomyocytes [J]. Materials Horizons, 2024 July 31. (IF=12.2)
[5] X. Li, J. Tie, Y. Sun, et al. Targeting DNM1L/DRP1-FIS1 axis inhibits high-grade glioma progression by impeding mitochondrial respiratory cristae remodeling [J]. Journal of Experimental & Clinical Cancer Research, 2024 September 30; 43(1):273. (IF=11.4)